Get the Stockscreener App
13.50
1.32%
-0.18
Hutchmed China Limited Adr stock is traded at $13.50, with a volume of 36,995.
It is down -1.32% in the last 24 hours and up +5.30% over the past month.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
See More
Previous Close:
$13.68
Open:
$13.52
24h Volume:
36,995
Relative Volume:
0.66
Market Cap:
$2.35B
Revenue:
$549.97M
Net Income/Loss:
$458.86M
P/E Ratio:
5.1456
EPS:
2.6236
Net Cash Flow:
$-89.06M
1W Performance:
-7.53%
1M Performance:
+5.30%
6M Performance:
-11.65%
1Y Performance:
-12.28%
1-Day Range:
$13.28
$13.58
1-Week Range:
$13.28
$14.10
52-Week Range:
$9.77
$16.33
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
13.50 | 2.35B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
18.52 | 59.16B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.25 | 48.11B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.44 | 41.51B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.30 | 30.70B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
543.40 | 23.31B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-26 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-03-26 | Upgrade | Daiwa Securities | Hold → Buy |
| Sep-22-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-13-25 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
| May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-03-21 | Initiated | Jefferies | Buy |
| Oct-02-20 | Initiated | Deutsche Bank | Buy |
| Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-20 | Initiated | Goldman | Buy |
| Nov-19-19 | Initiated | CLSA | Buy |
| Oct-23-19 | Reiterated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - GlobeNewswire Inc.
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.
HCM Q2 2023 Earnings: EPS Beat Consensus by 149.86% as Shares Edge HigherAnnual Report - dars.gov.et
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia
Trinity Delta Lighthouse: HUTCHMED - Vox Markets
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com
GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - GlobeNewswire
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media
HUTCHMED (HCM) lung cancer combo tops China Phase III trial - Stock Titan
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com
HUTCHMED (China) LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan
HUTCHMED (China) LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordAnalyst Earnings Estimate - careplusvn.com
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordFinancial Data - dars.gov.et
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordNet Income Trends - dars.gov.et
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordSegment Revenue Breakdown - dars.gov.et
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView
HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Deceleration Risk - careplusvn.com
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionProfit Margin Analysis - dars.gov.et
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Season Outlook - dars.gov.et
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Cycle Outlook - dars.gov.et
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionNet Income Trends - dars.gov.et
HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusStrangle Setup - careplusvn.com
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusMomentum Breakout Ideas - dars.gov.et
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusVolatility Skew - dars.gov.et
Hutchmed (HCM) Holds Near $12.47 as Biotech Sector Watches Support LevelFactor Rotation - careplusvn.com
HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com
REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView
HCM Q2 2023 Earnings: Strong EPS Beat Driven by Improved ProfitabilityEarnings Manipulation Risk - careplusvn.com
HCM Q2 2023 Earnings: Strong EPS Beat Driven by Improved ProfitabilityCash Flow Report - dars.gov.et
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):